BMS' Cobenfy Poised to Lead $17 Billion Schizophrenia Market Amid Generic Erosion
The schizophrenia drug market is anticipated to reach $17 billion by 2031, propelled by new launches despite the challenges posed by generic erosion[1][2]. Projected by GlobalData to grow from $8.4 billion in 2021 at a compound annual growth rate of 7.4%, this market expansion is driven by significant contributions from late-stage pipeline products[1]. Among the key players, Bristol Myers Squibb's Cobenfy, alongside other adjunctive therapies, is expected to dominate the schizophrenia market with potential revenues hitting $2.2 billion by 2031. This shift includes new market dynamics with anticipated approvals and challenges from generics, setting the stage for significant strategic impacts in the sector[2].
References
Explore Further
How will Bristol Myers Squibb's Cobenfy differentiate itself from other new therapies in the schizophrenia drug market?
What strategies might Bristol Myers Squibb employ to tackle the challenge of generic competition for Cobenfy?
In what ways can the anticipated patent expirations of current schizophrenia treatments impact the market dynamics?
How significant is the role of adjunctive therapies like Newron Pharmaceuticals’ evenamide in the projected growth of the schizophrenia market?
What are the potential hurdles for Cobenfy to achieve its projected sales of $2.2 billion in the schizophrenia market by 2031?